Case Report

Retention of Extended Release Nifedipine Capsules in a Patient with Enteric Stricture Causing Recurrent Small Bowel Obstruction

Authors: Wing C. Yeen, MD, MBA, Irwin H. Willis, MD, FACS

Abstract

Medication bezoars from extended release medication have been reported in the literature. This has become an increasing phenomenon with the popularity of extended release formulations, which aim to increase therapeutic compliance. We report on a patient who experienced recurrent bouts of small bowel obstruction, necessitating surgical exploration.


Key Points


* Pharmacobezoars is an increasing phenomenon with the popularity of extended release formulation of medication aiming to increase therapeutic compliance.


* Presenting symptoms due to intermittent or complete obstruction include weight loss, nausea, vomiting and early satiety.


* Bezoars may form as a result of GI surgery, pathologic or iatrogenic narrowing of the GI anatomy or slowed GI motility.


* Physicians should be aware of the potential complications in high risk patients.


* A detailed history and physical examination may prevent pharmacobezoars in those with prior peptic ulcer disease, cancer, or other conditions potentially leading to narrowing of the gastrointestinal lumen.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Elgood C. A treatise on the bezoar stone: By the late Mahmud bin Masud the Imad-ul-din the physician of Ispahan. Ann Med Hist 1935;7:73–80.
 
2. Stack PE, Thomas E. Pharmacobezoar: An evolving new entity. Dig Dis 1995;13:356–364.
 
3. Bogacz K, Caldron P. Enetric-coated aspirin bezoar: elevation of serum salicylate level by barium study; case report and review of medical management. Am J Med 1987;83:783–786.
 
4. Prisant LM, Carr AA, Bottini PB, et al. Nifedipine GITS (gastrointestinal therapeutic system) bezoar.Arch Intern Med 1991;151:1868–1869.
 
5. Shepherd M. Bezoar formed by fragments of extended-release nifedipine tablets. Clin Pharm1993;12:849–852.
 
6. Potyk D. Intestinal obstruction from impacted antacid tablets. N Eng J Med 1970;283:134–135.
 
7. Brettschneider L, Monafo W, Osborne DP. Intestinal obstruction due to antacid gels.Gestroenterology 1965;49:291–294.
 
8. Korenman MD, Stubbs MB, Fish JC. Intestinal obstruction from medication bezoars. JAMA1978;240:54–55.
 
9. Harris FC. Pylori stenosis hold-up of enteric-coated aspirin tablets. Br J Surg 1973;60:979–981.
 
10. Sogge MR, Griffith JL, Sinar DR, Mayes GR. Lavage to remove entericcoated aspirin and gastric outlet obstruction. Ann Intern Med 1977;87: 721–722.
 
11. Algozzine GJ, Hill G, Scoggins WG, et al. Sucralfate bezoar. N Eng J Med 1983;309:1387.
 
12. Lewis JH. Esophageal and small bowel obstruction from guar gumcontaining ‘diet pills’: Analysis of 26 cases reported in the Food and Drug Administration. Am J Gastroenterol 1992;87:1424–1428.
 
13. Cohen MI, Winslow PR, Boley SJ. Intestinal obstruction associated with cholestyramine therapy. N Eng J Med 1969;280:1285–1286.
 
14. Agha FP, Nostrant TT, Fiddian-Green RG. ‘Giant colonic bezoar’: A medication bezoar due to psylliumseed husks. Am J gastroenterol 1984; 79:319–321.
 
15. Stack PE, Patel NR, Young MF, et al. Pharmacobezoars: The irony of the antidote. First case of nifedipine XL bezoar. J Clin Gastroenterol 1994;19:264–271.
 
16. Calabuig R, Navarro S, Carrio I, et al. Gastric emptying and bezoars. Am J Surg 1989;157:287–290.
 
17. Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system: A controlled release formulation of nifedipine. Am J Med 1987;83:10–14.
 
18. Gasperino JL. Procardia XL bezoar. Arch Intern Med 1992;152:880–881.
 
19. Raufman JP, Soldevila-Pico C. Pseudopolyposis medicamentosus. Gastrointest Endosc1993;39:213–214.
 
20. Kwon HY, Scott RL, Mulloy JP. Small bowel Procardia XL tablet bezoar mimicking cystic pneumatosis intestinalis. Abdom Imaging 1996; 21:142–144.
 
21. Melchreit R, McGowan G, Hyams JS. “Colonic crunch” sign in sunflower- seed bezoar. N Eng J Med1984;310:1748–1749.
 
22. Greenstein DB, Wilcox CM, Frontin K, et al. Nifedipine (Procardia XL) as a cause of false positive results on barium study. Southern Med J 1994;87:808–810.